Abstract
Melanoma incidence is growing at a faster rate than any other human malignancy. Wild-type (wt) p53 is important in both G1 and G2 cell cycle arrest, and cyclin D1 (CD1) is necessary for G1→S progression in melanoma cells. We reported that an adenoviral vector containing wt p53 significantly reduced [3H]thymidine uptake in melanoma cells containing mutant but not wt p53. Subsequently we showed that CD1 decreased melanoma proliferation and increased apoptosis. We now extend these findings by evaluating the effect on preformed melanomas of (1) intratumoral therapy with wt p53 alone, (2) wt p53 in combination with antisense (AS) CD1, both short (≤14 days) and longer term, and (3) doubling the dose or repeat doses of wt p53 or AS CD1. Two melanoma cells lines that metastasize in SCID mice (451 and 1205) were used, one containing a p53 mutation (451) and the other a normal p53 gene sequence (1205). Compared to injection with a control adenoviral vector containing β-galactosidase (LacZ), intratumoral injection of wt p53 slowed the growth of tumors formed from 451 cells. Using 5×108 plaque forming units as our standard intratumoral dose, neither doubling the dose of LacZ, p53 or AS CD1, nor repeat doses of the vectors, was as effective as combined therapy with wt p53+AS CD1, which resulted in the shrinkage of all tumors treated and 4/7 (57%) tumors vanished. No tumors treated with wt p53 or AS CD1 alone vanished. Wt p53+AS CD1 treatment resulted in significantly more cells undergoing apoptosis compared to either therapy alone. In summary, combining the separately effective treatment vectors p53 and AS CD1 led to an enhanced growth-suppressive and apoptotic effect, supporting a role for combination gene therapy to treat human malignant melanoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
ACS. Cancer Facts and Figures 2002 Atlanta: American Cancer Society 2002
Brash DE, Rudolph JA, Simon JA et al. A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma Proc Natl Acad Sci USA 1991 88: 10124–10128
Lee JY, Dong SM, Shin MS et al. Genetic alterations of p16INK4a and p53 genes in sporadic dysplastic nevus Biochem Biophys Res Commun 1997 237: 667–672
Weiss J, Heine M, Arden KC et al. Mutation and expression of TP53 in malignant melanomas Recent Results Cancer Res 1995 139: 137–154
Hartmann A, Blaszyk H, Cunningham JS et al. Overexpression and mutations of p53 in metastatic malignant melanomas Int J Cancer 1996 67: 313–317
Ley RD, Applegate LA, Padilla RS et al. Ultraviolet radiation-induced malignant melanoma in Monodelphia domestica Photochem Photobiol 1989 50: 1–5
Romerdahl CA, Stephens LC, Bucana C et al. The role of ultraviolet radiation in the induction of melanocytic skin tumors in inbred mice Cancer Commun 1989 1: 209–216
Berking C, Takemoto R, Satyamoorthy K et al. Basic fibroblast growth factor and ultraviolet B transform melanocytes in human skin Am J Pathol 2001 158: 943–953
Helin K, Harlow E . The retinoblastoma protein as a transcriptional repressor Trends Cell Biol 1992 3: 43–46
Deng C, Zhang P, Harper JW et al. Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control Cell 1995 82: 675–684
Evdokiou A, Raggatt LJ, Atkins GJ et al. Calcitonin receptor-mediated growth suppression of HEK-293 cells is accompanied by induction of p21WAF1/CIP1 and G2/M arrest [In Process Citation] Mol Endocrinol 1999 13: 1738–1750
Zhan Q, Antinore MJ, Wang XW et al. Association with Cdc2 and inhibition of Cdc2/Cyclin B1 kinase activity by the p53-regulated protein Gadd45 Oncogene 1999 18: 2892–2900
Hinds PW, Dowdy SF, Eaton EN et al. Function of a human cyclin gene as an oncogene Proc Natl Acad Sci USA 1994 91: 709–713
Matsushime HD, Quelle E, Shurtleff SA et al. D-type cyclin-dependent kinase activity in mammalian cells Mol Cell Biol 1994 14: 2066–2076
Rieber MS, Rieber M . Suppression of cyclin D1 but not cdk4 or cyclin A with induction of melanoma terminal differentiation Biochem Biophys Res Commun 1995 216: 422–427
Bartkova J, Lukas J, Guldberg P et al. The p16-cyclin D1/Cdk4-pRb pathway as a functional unit frequently altered in melanoma pathogenesis Cancer Res 1996 56: 5475–5483
Satyamoorthy K, Chehab NH, Waterman MJ et al. Aberrant regulation and function of wild-type p53 in radioresistant melanoma cells Cell Growth Differ 2000 11: 467–474
Sauter ER, Nesbit M, Litwin S et al. Antisense cyclin D1 induces apoptosis and tumor shrinkage in human squamous carcinomas Cancer Res 1999 59: 4876–4881
Sauter ER, Yeo UC, van Stemm A et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma Cancer Res 2002 3200–3206
Jenq W, Wu SJ, Kefalides NA . Expression of the alpha 2-subunit of laminin correlates with increased cell adhesion and metastatic propensity Differentiation 1994 58: 29–36
Herlyn D, Iliopoulos D, Jensen PJ et al. In vitro properties of human melanoma cells metastatic in nude mice Cancer Res 1990 50: 2296–2302
Iliopoulos D, Ernst C, Steplewski Z et al. Inhibition of metastases of a human melanoma xenograft by monoclonal antibody to the GD2/GD3 gangliosides J Natl Cancer Inst 1989 81: 440–444
Graham FL, Smiley J, Russell WC et al. Characteristics of a human cell line transformed by DNA from human adenovirus type 5 J Gen Virol 1977 36: 59–74
El-Deiry WS, Tokino T, Velculescu VE et al. WAF1, a potential mediator of p53 tumor suppression Cell 1993 75: 817–825
Wilkinson GWG, Akrigg A . Constitutive and enhanced expression from the CMV major IE promoter in a defective adenovirus vector Nucleic Acids Res 1992 20: 2233–2239
Ranheim TS, Shisler J, Horton TM et al. Characterization of mutants within the gene for the adenovirus E3 q4.7-kilodalton protein which prevents cytolysis by tumor necrosis factor J Virol 1993 67: 2159–2167
Hung W-C, Huang J-S, Chuang L-Y . Antisense oligodeoxynucleotides targeted against different regions of cyclin D1 mRNA may exert different inhibitory effects on cell growth and gene expression Biochem Biophys Res Commun 1996 220: 719–723
Schrump DS, Chen A, Consoli U . Inhibition of lung cancer proliferation by antisense cyclin D Cancer Gene Ther 1996 3: 131–135
Kornmann M, Arber N, Korc M . Inhibition of basal and mitogen-stimulated pancreatic cancer cell growth by cyclin D1 antisense is associated with loss of tumorigenicity and potentiation of cytotoxicity to cisplatinum J Clin Invest 1998 101: 344–352
Driscoll B, Wu L, Buckley S et al. Cyclin D1 antisense RNA destabilizes pRb and retards lung cancer cell growth Am J Physiol 1997 273: L941–L949
Arber N, Doki Y, Han E-H et al. Antisense to cyclin D1 inhibits the growth and tumorigenicity of human colon cancer cells Cancer Res 1997 57: 1569–1574
Li Z, Rakkar A, Katayose Y et al. Efficacy of multiple administrations of a recombinant adenovirus expressing wild-type p53 in an immune-competent mouse tumor model Gene Ther 1998 5: 605–613
Powell SN, DeFrank JS, Connell P et al. Differential sensitivity of p53(−) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay Cancer Res 1995 55: 1643–1648
St John LS, Sauter ER, Herlyn M et al. Endogenous p53 gene status predicts the response of human squamous cell carcinomas to wild-type p53 Cancer Gene Ther 2000 7: 749–756
Putzer BM, Bramson JL, Addison CL et al. Combination therapy with interleukin-2 and wild-type p53 expressed by adenoviral vectors potentiates tumor regression in a murine model of breast cancer Hum Gene Ther 1998 9: 707–718
Acknowledgements
Supported in part by National Institutes of Health Grants DE-00380 and CA-25874.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sauter, E., Takemoto, R., Litwin, S. et al. p53 alone or in combination with antisense cyclin D1 induces apoptosis and reduces tumor size in human melanoma. Cancer Gene Ther 9, 807–812 (2002). https://doi.org/10.1038/sj.cgt.7700492
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700492
Keywords
This article is cited by
-
Star-PAP controls HPV E6 regulation of p53 and sensitizes cells to VP-16
Oncogene (2014)
-
Experimental research for specific down-regulated expression of p53 gene by individual antisense RNA in vitro
The Chinese-German Journal of Clinical Oncology (2007)
-
Adenovirus-mediated TA-p73β gene transfer increases chemosensitivity of human malignant melanomas
Apoptosis (2006)
-
Cyclin D1 is essential for neoplastic transformation induced by both E6/E7 and E6/E7/ErbB-2 cooperation in normal cells
Oncogene (2004)
-
Apoptosis and melanoma chemoresistance
Oncogene (2003)